Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Merkel Cell 2Neuroendocrine Tumors 1Carcinoma 1

Interventions

pembrolizumab 8Nivolumab 4fludarabine 2Cyclophosphamide 2sonidegib 1obinutuzumab 1methyl 5-aminolevulinate 1lutetium Lu 177 dotatate 1fludarabine phosphate 1durvalumab 1daromun 1cabozantinib 1avelumab 1atezolizumab 1advexin 1Tomography, Optical Coherence 1Therapeutics 1Taxes 1Specimen Handling 1Radiotherapy 1ProMune 1Pemetrexed 1Paclitaxel 1Oncolytic Virotherapy 1Mesna 1Magnetic Resonance Spectroscopy 1MAPRE1 protein, human 1Lutetium-177 1Interleukin-2 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × lutetium Lu 177 dotatate × Dermatologic × Clear all
NCT04261855 2026-03-27

GoTHAM

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Active not recruiting
19 enrolled
DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡